Fig. 1From: Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principleCartoon illustrating the in vivo procedure: 5 × 106 of either PC3-PIP (PSMA positive) or PC3 (PSMA negative) cells were injected subcutaneously (s.c.) in the flank of mice. 20 days later, 124I-scFvD2B was administered i.v. and after 15–24 h both ImmunoPET imaging and ex vivo biodistribution were performedBack to article page